Technology | October 19, 2008

FISH Offers Introducer Sheath, Closure in One Device

Morris Innovative offers the FISH (Femoral Introducer Sheath and Hemostasis) Device that combines one sheath as both an introducer and closure device.

The FISH utilizes a sleeve of extracellular matrix, known as small intestinal submucosa (SIS), pre-mounted on a sheath introducer to serve as the closure mechanism. The SIS is remodeled into native arterial wall tissue in about 30 days, the company said. Instead of the formation of scar tissue, viable host tissue is formed at the arteriotomy with the use of the FISH device. The company said this allows easy reaccess during future procedures.

Because FISH uses a single introducer and hemostasis sheath, the time for deployment and the time required in the catheterization lab at the conclusion of the diagnostic or interventional procedure should be dramatically reduced, the manufacturer said.

Follow up interviews with patients participating in the clinical trial of the device indicated minimal patient discomfort. FISH works from inside the vessel, enhancing clotting mechanisms, while avoiding impingement and injury to the nerve tissue that resides on the external surface of and adjacent to the vessel. The clinical trials also showed significant reductions in time to hemostasis and time to ambulation for the patients.

The complication rate of the device after 200 patients receiving the device is 0.5 percent. The company said this rate is among the lowest for this type of trial and can be attributed to the reversibility of the device, as well as the infection resistant properties of the SIS. In the event of a complication, FISH biomaterial can easily be removed by using the safety sutures, and administering manual compression to close the arterial opening.

The company launches the device in October 2008.

Related Content

Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.
Technology | Vascular Closure Devices | December 14, 2017
Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt...
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices | October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Overlay Init